OBJECTIVE: The aim of this study was to determine the effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes. METHODS: A randomized, blinded, multicenter, placebo-controlled parallel-group 8-week trial with 205 women (95 African American, 102 white, 8 other) was conducted between July 2009 and June 2010. The participants received escitalopram (10-20 mg/d) or placebo. Insomnia symptoms (Insomnia Severity Index [ISI]) and subjective sleep quality (Pittsburgh Sleep Quality Index [PSQI]) at weeks 4 and 8 were the prespecified secondary outcomes. A total of 199 women (97%) provided ISI data, and 194 (95%) women provided PSQI data at follow-up. RESULTS: At baseline, mean hot flash frequency was 9.78 per day (SD, 5.60), mean ISI was 11.4 (SD, 6.3), and mean PSQI was 8.0 (SD, 3.7). Treatment with escitalopram reduced ISI at week 8 (mean difference, -2.00; 95% CI, -3.43 to -0.57; P < 0.001 overall treatment effect), with mean differences of -4.73 (95% CI, -5.72 to -3.75) in the escitalopram group and -2.73 (95% CI, -3.78 to -1.69) in the placebo group. The reduction in PSQI was greater in the escitalopram than in the placebo group at week 8 (mean difference, -1.31; 95% CI, -2.14 to -0.49; P < 0.001 overall treatment effect). Clinical improvement in insomnia symptoms and subjective sleep quality (≥50% decreases in ISI and PSQI from baseline) was observed more frequently in the escitalopram group than in the placebo group (ISI, 50.0% vs 35.4%, P = 0.04; PSQI, 29.6% vs 19.2%, P = 0.09). CONCLUSIONS: Among healthy perimenopausal and postmenopausal women with hot flashes, escitalopram at 10 to 20 mg/day compared with placebo reduced insomnia symptoms and improved subjective sleep quality at 8 weeks of follow-up.
OBJECTIVE: The aim of this study was to determine the effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes. METHODS: A randomized, blinded, multicenter, placebo-controlled parallel-group 8-week trial with 205 women (95 African American, 102 white, 8 other) was conducted between July 2009 and June 2010. The participants received escitalopram (10-20 mg/d) or placebo. Insomnia symptoms (Insomnia Severity Index [ISI]) and subjective sleep quality (Pittsburgh Sleep Quality Index [PSQI]) at weeks 4 and 8 were the prespecified secondary outcomes. A total of 199 women (97%) provided ISI data, and 194 (95%) women provided PSQI data at follow-up. RESULTS: At baseline, mean hot flash frequency was 9.78 per day (SD, 5.60), mean ISI was 11.4 (SD, 6.3), and mean PSQI was 8.0 (SD, 3.7). Treatment with escitalopram reduced ISI at week 8 (mean difference, -2.00; 95% CI, -3.43 to -0.57; P < 0.001 overall treatment effect), with mean differences of -4.73 (95% CI, -5.72 to -3.75) in the escitalopram group and -2.73 (95% CI, -3.78 to -1.69) in the placebo group. The reduction in PSQI was greater in the escitalopram than in the placebo group at week 8 (mean difference, -1.31; 95% CI, -2.14 to -0.49; P < 0.001 overall treatment effect). Clinical improvement in insomnia symptoms and subjective sleep quality (≥50% decreases in ISI and PSQI from baseline) was observed more frequently in the escitalopram group than in the placebo group (ISI, 50.0% vs 35.4%, P = 0.04; PSQI, 29.6% vs 19.2%, P = 0.09). CONCLUSIONS: Among healthy perimenopausal and postmenopausal women with hot flashes, escitalopram at 10 to 20 mg/day compared with placebo reduced insomnia symptoms and improved subjective sleep quality at 8 weeks of follow-up.
Authors: Eila Suvanto-Luukkonen; Riitta Koivunen; Helena Sundström; Risto Bloigu; Eija Karjalainen; Leena Häivä-Mällinen; Juha S Tapanainen Journal: Menopause Date: 2005 Jan-Feb Impact factor: 2.953
Authors: Ryne Paulose-Ram; Marc A Safran; Bruce S Jonas; Qiuping Gu; Denise Orwig Journal: Pharmacoepidemiol Drug Saf Date: 2007-05 Impact factor: 2.890
Authors: Daniel J Buysse; Anne Germain; Douglas E Moul; Peter L Franzen; Laurie K Brar; Mary E Fletcher; Amy Begley; Patricia R Houck; Sati Mazumdar; Charles F Reynolds; Timothy H Monk Journal: Arch Intern Med Date: 2011-01-24
Authors: Heidi D Nelson; Kimberly K Vesco; Elizabeth Haney; Rongwei Fu; Anne Nedrow; Jill Miller; Christina Nicolaidis; Miranda Walker; Linda Humphrey Journal: JAMA Date: 2006-05-03 Impact factor: 56.272
Authors: Fiona C Baker; Adrian R Willoughby; Stephanie A Sassoon; Ian M Colrain; Massimiliano de Zambotti Journal: Psychoneuroendocrinology Date: 2015-06-17 Impact factor: 4.905
Authors: Teletia R Taylor; Kendra Van Kirk; Denia Tapscott; Monet Bernard; Juliana Llano; Thomas A Mellman Journal: J Racial Ethn Health Disparities Date: 2014-12-06
Authors: Misti L Paudel; Brent C Taylor; Tien N Vo; Allyson M Kats; John T Schousboe; Li-Yung Lui; Charles E McCulloch; Lisa Langsetmo; Sonia Ancoli-Israel; Susan Redline; Kristine Yaffe; Katie L Stone; Teresa A Hillier; Kristine E Ensrud Journal: Sleep Date: 2017-04-01 Impact factor: 5.849
Authors: Haeseong Park; Rui Qin; Thomas J Smith; Pamela J Atherton; Debra L Barton; Keren Sturtz; Shaker R Dakhil; Daniel M Anderson; Kathleen Flynn; Suneetha Puttabasavaiah; Nguyet Anh Le-Lindqwister; Gilbert D A Padula; Charles L Loprinzi Journal: Menopause Date: 2015-06 Impact factor: 2.953
Authors: Nikkie Aarts; Lisette A Zuurbier; Raymond Noordam; Albert Hofman; Henning Tiemeier; Bruno H Stricker; Loes E Visser Journal: J Clin Sleep Med Date: 2016-07-15 Impact factor: 4.062